Abstract:Objective Recurrence remains the main cause of the poor prognosis in stage I-IIIA lung squamous cell carcinoma (LUSC) after surgical resection. In the present study, we aimed to identify the long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) related to the recurrence of stage I-IIIA LUSC. Moreover, we constructed a risk assessment model to predict the recurrence of LUSC patients. Methods RNA sequencing data (including miRNAs, lncRNAs, and mRNAs) and relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database. The differentially expressed lncRNAs, miRNAs, and mRNAs were identified using the “DESeq2” package of the R language. Univariate Cox proportional hazards regression analysis and Kaplan-Meier curve were used to identify recurrence-related genes. Stepwise multivariate Cox regression analysis was carried out to establish a risk model for predicting recurrence in the training cohort. Moreover, Kaplan-Meier curves and receiver operating characteristic (ROC) curves were adopted to examine the predictive performance of the signature in the training cohort, validation cohort, and entire cohort. Results Based on the TCGA database, we analyzed the differentially expressed genes (DEGs) among 27 patients with recurrent stage I-IIIA LUSC and 134 patients with non-recurrent stage I-IIIA LUSC, and identified 431 lncRNAs, 36 miRNAs, and 746 mRNAs with different expression levels. Out of these DEGs, the optimal combination of DEGs was finally determined, and a nine-joint RNA molecular signature was constructed for clinical prediction of recurrence, including LINC02683, AC244517.5, LINC02418, LINC01322, AC011468.3, hsa-mir-6825, AC020637.1, AC027117.2, and SERPINB12. The ROC curve proved that the model had good predictive performance in predicting recurrence. The area under the curve (AUC) of the prognostic model for recurrence-free survival (RFS) was 0.989 at 3 years and 0.958 at 5 years (in the training set). The combined RNA signature also revealed good predictive performance in predicting the recurrence in the validation cohort and entire cohort. Conclusions In the present study, we constructed a nine-joint RNA molecular signature for recurrence prediction of stage I-IIIA LUSC. Collectively, our findings provided new and valuable clinical evidence for predicting the recurrence and targeted treatment of stage I-IIIA LUSC.

A Qualitative Transcriptional Signature of Recurrence Risk for Stages II-III Gastric Cancer Patients after Surgical Resection.

A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage I-III Bladder Cancer Patients After Surgical Resection.

Comprehensive Analysis of Multi-Omics Data of Recurrent Gliomas Identifies a Recurrence-Related Signature As a Novel Prognostic Marker.

Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

A Qualitative Transcriptional Signature for Predicting the Biochemical Recurrence Risk of Prostate Cancer Patients after Radical Prostatectomy

Identifying Reproducible Molecular Biomarkers for Gastric Cancer Metastasis with the Aid of Recurrence Information

A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer

A Rank-Based Transcriptional Signature for Predicting Relapse Risk of Stage Ii Colorectal Cancer Identified with Proper Data Sources

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated with Platinum-Taxane Adjuvant Chemotherapy

Recurrence-associated Gene Signature Optimizes Recurrence-Free Survival Prediction of Colorectal Cancer.

A Qualitative Transcriptional Signature for Predicting the Recurrence Risk of Prostate Cancer Patients after Radical Prostatectomy

A Novel 9-Gene Signature for the Prediction of Postoperative Recurrence in Stage II/III Colorectal Cancer

A Qualitative Transcriptional Signature For The Risk Assessment Of Precancerous Colorectal Lesions

A molecular signature for the prediction of recurrence in colorectal cancer

Combination of Hsa-Mir-375 and Hsa-Mir-142-5p As a Predictor for Recurrence Risk in Gastric Cancer Patients Following Surgical Resection.

Two Novel Qualitative Transcriptional Signatures Robustly Applicable to Non‐research‐oriented Colorectal Cancer Samples with Low‐quality RNA

Identifying Predictive Factors of Recurrence after Radical Resection in Gastric Cancer by RNA Immune-oncology Panel.

A Circrna Signature Predicts Postoperative Recurrence in Stage II/III Colon Cancer

A Network‐based Predictive Gene Expression Signature for Recurrence Risks in Stage II Colorectal Cancer

Genome‐wide Identification of a Novel Mirna‐based Signature to Predict Recurrence in Patients with Gastric Cancer

A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma